Drug Discovery Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Drug Discovery stocks.

Drug Discovery Stocks Recent News

Date Stock Title
Jul 18 WGS What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?
Jul 18 LXRX Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Jul 18 TWST Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
Jul 18 HTGC Hercules Capital Announces Date for Release of Second Quarter 2024 Financial Results and Conference Call
Jul 18 GLW A Look Back at Electronic Components Stocks' Q1 Earnings: Littelfuse (NASDAQ:LFUS) Vs The Rest Of The Pack
Jul 18 GLW Q4 Rundown: Coherent (NYSE:COHR) Vs Other Electronic Components Stocks
Jul 17 HTGC Hercules Capital (HTGC) Stock Moves -0.51%: What You Should Know
Jul 17 LXRX FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
Jul 17 HTGC Pindrop Secures $100 Million Financing To Accelerate Fraud And Deepfake Detection Technologies
Jul 17 WGS Small Caps Climb on Interest Rate Cut Expectations: 5 Picks
Jul 17 RLAY Caribou lays off staff; Roche walks away from Relay
Jul 17 HTGC Hercules Capital Receives SBA Approval for Its Fourth SBIC License
Jul 17 GLW Spotting Winners: Coherent (NYSE:COHR) And Electronic Components Stocks In Q4
Jul 16 LXRX Lexicon gains as diabetes therapy undergoes FDA review
Jul 16 LXRX Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
Jul 16 GLW Q1 Earnings Outperformers: nLIGHT (NASDAQ:LASR) And The Rest Of The Electronic Components Stocks
Jul 15 GLW 4 reasons hardware will drive big tech earnings: Fund manager
Jul 15 TWST Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
Jul 15 IDYA Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts
Jul 15 LXRX New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Drug Discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as
classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.
Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity was about US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.
Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.

Browse All Tags